Peer-reviewed veterinary case report
High platelet-to-albumin ratio may signal worse outlook in dogs
By Jeffcoat, Meghan E et al.·Published in American journal of veterinary research·2025·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Elevated platelet-to-albumin ratio may predict worsened prognosis in dogs with appendicular osteosarcoma: a preliminary study.
- Species:
- dog
Plain-English summary
A group of dogs with bone cancer (osteosarcoma) was studied to see if certain blood test results could predict how long they might live or how quickly their disease would progress. Researchers found that dogs with a higher platelet-to-albumin ratio (PAR) had a shorter time before their cancer worsened, averaging about 115 days compared to 138 days for those with a lower ratio. However, the level of cholesterol in their blood did not seem to affect their survival time. This suggests that monitoring the PAR could help veterinarians better understand the prognosis for dogs with this type of cancer.
People also search for: dog osteosarcoma prognosis · elevated platelet-to-albumin ratio in dogs · dog cancer survival time
Abstract
OBJECTIVE: To evaluate the associations between the platelet-to-albumin ratio (PAR), platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, neutrophil-to-lymphocyte ratio, and progression-free interval (PFI) and median survival time (MST) in dogs with osteosarcoma. The secondary objective was to evaluate the prognostic value of serum cholesterol in the same population. METHODS: This was a preliminary retrospective study on dogs with appendicular osteosarcoma. Records from 2010 to 2024 were searched for dogs undergoing treatment for osteosarcoma. Data collected included serochemical and hematological values (platelet, monocyte, lymphocyte, neutrophil, albumin, ALP, and cholesterol levels). Variables were assessed for association with PFI and survival time via Kaplan-Meier and Cox proportional hazards analyses. RESULTS: 60 dogs met the inclusion criteria. 50 of 60 dogs were included for survival analysis, and 42 of 60 were included for disease progression. The PAR was significantly associated with decreased PFI, being elevated in 13 dogs (median PFI, 115 days; 95% CI, 73 to 171) and low in 29 dogs (median PFI, 138 days; 95% CI, 95 to 272). Serum cholesterol had no association with PFI (median, 147 days; 95% CI, 95 to 272) or MST (median, 219; 95% CI, 138 to 292). CONCLUSIONS: Elevated PAR was significantly associated with decreased PFI. There was no association between elevated serum cholesterol and MST or PFI. CLINICAL RELEVANCE: These results suggest that in dogs with osteosarcoma, an elevated PAR may be associated with a decreased PFI and therefore may have prognostic significance.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40675182/